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Massive acetaminophen (N-acetyl-p-aminophenol; APAP) ingestion is characterized by a rapid onset of mitochondrial dysfunction,
including metabolic acidosis, lactemia, and altered mental status without hepatotoxicity which may not respond to the standard
doses of N-acetylcysteine (NAC). A 64-year-old woman without medical history presented comatose after an ingestion of 208
tablets of Tylenol PM (APAP 500 mg and diphenhydramine 25 mg). The initial APAP concentration measured 1,017 𝜇g/mL
(therapeutic range 10-30 𝜇g/mL), and elevated anion gap metabolic acidosis, lactemia, and 5-oxoprolinemia were detected. Highdose intravenous (IV) NAC, 4-methylpyrazole (4-MP), and hemodialysis (HD) were initiated. She was transferred to a liver
transplant center and continued both NAC and HD therapies until complete resolution of metabolic acidosis and coma without
developing hepatitis. She was discharged without sequelae. This is the fourth highest APAP concentration recorded in a surviving
patient. Moreover, this is the first report of a novel “triple therapy” using NAC, 4-MP, and HD in the setting of massive APAP
ingestion that presents with coma, elevated anion gap metabolic acidosis, and lactemia. Emergency physicians should recognize
these critically ill patients and consider high-dose NAC, 4-MP, and HD to be initiated in the emergency department (ED).

1. Introduction
In the United States, APAP toxicity is the most common
cause of acute hepatic failure and is the second most common cause of liver failure requiring transplantation. The
Annual Report of the American Association Poison Control
Centers’ National Poison Data System documented 49,417
cases of APAP exposure in 2016 and 21,776 cases of APAP
combination medication exposure. APAP alone and APAP
combinations resulted in 92 and 42 deaths, respectively [1].
Massive APAP ingestion is characterized by rapid onset
of mitochondrial dysfunction, including metabolic acidosis,
lactemia, and altered mental status without hepatotoxicity
[2]. Metabolic acidosis in the setting of APAP poisoning
is typically a late-onset process secondary to liver failure.
However, when metabolic acidosis is present early after

ingestion, it may be secondary to overwhelming N-acetylp-benzoquinone imine (NAPQI) presence. APAP can also
cause 5-oxoprolinemia associated with depletion of liver
glutathione stores and may contribute to metabolic acidosis
early in clinical presentation, unassociated with liver failure
[3, 4]. This is typically present when glutathione stores are
exhausted, most often in those with genetic glutathione
disorders and chronic APAP ingestion, but it has rarely been
associated with acute toxicity [4, 5].
This case report details the case of a woman who intentionally ingested a massive amount of APAP and demonstrated both mitochondrial dysfunction and 5-oxoprolinemia
contributing to metabolic acidosis, lactemia, and altered
mental status. The authors of this paper suggest a novel
approach to massive APAP toxicity through concomitant use
of high-dose, IV NAC, 4-MP, and HD. This case represented

2
the fourth highest APAP concentration in the literature
of a surviving patient, as well as the first known report
of administering 4-MP—a CYP450 2E1 inhibitor—in the
successful management [6].

2. Case Presentation
A 64-year-old woman with no past medical history and no
prescribed medications was found unresponsive at home
after ingestion of 208 tablets of Tylenol PM (APAP 500
mg with diphenhydramine 25 mg) approximately three hours
prior to transportation to the ED. She was endotracheally
intubated by prehospital staff due to decreased level of
consciousness, vomitus, and agonal respiration. On arrival
to the ED, vital signs included temperature of 33.9∘ C, heart
rate of 57 bpm, blood pressure of 139/102 mmHg, respiratory
rate of 19 rpm, and oxygen saturation of 99% on 100%
FiO2 . Physical examination demonstrated a Glasgow Coma
Scale score 3 without spontaneous respiration. The patient
subsequently became hypotensive requiring five IV pushdose epinephrine doses (total 100 𝜇g), followed by dopamine
(10 𝜇g/kg/min increased to 15 𝜇g/kg/min), and then a
norepinephrine infusion (10 𝜇g/min). An electrocardiogram
(ECG) showed sinus rhythm of 58 bpm, PR of 144 ms,
QRS of 112 ms, and QTc of 659 ms. Serum chemistries
measured as follows: lactate 7.6 mmol/L (0.5-1.0 mmol/L),
glucose 193 mg/dL (70-100 mg/dL), Na+ 142 mEq/L (136144 mEq/L), K+ 3.2 mEq/L (3.7-5.2 mEq/L), Cl− 110 mmol/L
(96-106 mmol/L), CO2 18 mmol/L (20-29 mmol/L), BUN
16 mg/dL (7-20 mg/dL), Cr 1.17 mg/dL (0.6-1.1 mg/dL), AST
21 IU/L (10-34 IU/L), ALT 99 IU/L (8-37 IU/L), and INR
1.2 (0.8-1.1). Initial ABG measured as follows: pH 7.32 (7.357.45), pCO2 30 mmHg (35-45 mmHg), pO2 249 mmHg (80100 mmHg), and HCO3 16 (CMV FiO2 65%, PEEP 6, RR
16, and TV 500 mL). Initial serum APAP concentration
measured 1,017 𝜇g/mL. Serum salicylate and ethanol concentrations measured 7 mg/dL and negative, respectively.
A preliminary urine drug screen of abuse detected only
methadone. Expanded serum liquid chromatography/mass
spectroscopy detected caffeine, dihydrocodeine/hydrocodol,
lidocaine, monoethylglycinexylidide, and diphenhydramine.
A chest X-ray revealed mild interstitial edema. Head computed tomography was unremarkable. The patient was admitted to the intensive care unit. There was no repeat ECG
performed prior to transfer to transplant center; however, no
dysrhythmias were observed on telemetry monitoring.
The medical toxicology service was consulted and recommended IV sodium bicarbonate (for prolonged QRS
interval), IV NAC, IV 4-MP (15 mg/kg), and immediate HD.
APAP concentration decreased to 825 𝜇g/mL after initiation
of IV NAC, and serial concentrations exponentially decreased
during “triple therapy” (Figures 1 and 2). During HD, the IV
NAC rate of administration was doubled to 200 mg/kg and
then tripled to 300 mg/kg, and a subsequent dose of IV 4MP 10 mg/kg was administered; these were performed due to
concern of HD removal of both antidotes.
The patient’s mental status improved during HD; however, she did not follow commands. Due to concern for
potential severe liver injury given the massive initial APAP
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concentration and lack of institutional transplant services,
she was transferred to a liver transplant center on hospital day
one. On arrival to the liver transplant center, she was maintained on IV NAC and received an additional HD treatment.
4-MP was not readministered. IV NAC was discontinued
when APAP concentrations were undetectable. The patient
was awake and following commands but failed extubation
due to respiratory distress and pneumonia. She was ultimately
extubated to BiPAP and discharged to an inpatient psychiatry
unit approximately eight days after ED presentation in a
normal state of health.

3. Discussion
Massive APAP ingestion results in saturation of hepatic
sulfation and glucuronidation which leads to excessive
metabolism via hepatic CYP450 2E1 to the toxic metabolite,
NAPQI. NAPQI inhibits mitochondrial respiration and
contributes to cellular toxicity and metabolic acidosis [2].
Accumulation of the organic acid, 5-oxoproline, may also
contribute to the metabolic acidosis. Although typically
caused by genetic glutathione deficiencies, by chronic
APAP use, or with coexisting conditions such as sepsis,
malnutrition, or pregnancy, 5-oxoprolinemia may be present
in acute, massive APAP ingestion alone [4, 5]. 5-Oxoproline is
an intermediate in the gamma-glutamyl pathway, responsible
for regenerating glutathione and for transporting amino
acid into the cytosol. Normal glutathione concentrations
are required for negative feedback on the enzyme gammaglutamyl cysteine synthase. When glutathione stores are
depleted, there is overproduction of gamma-glutamyl
cysteine, which is partially metabolized to 5-oxoproline,
ultimately leading to acidosis. In this patient, given her
coexisting 5-oxoprolinemia, it is logical that both NAPQI
and organic acid accumulation contributed to her condition.
The association with altered mental status after APAP
ingestion with 5-oxoprolinemia has been reported [4, 5].
Standardly accepted treatment of APAP toxicity includes
restoration of glutathione stores with NAC administration.
However, given the considerable NAPQI formation in the setting of massive APAP ingestion, administration of a CYP450
2E1 substrate such as 4-MP or ethanol may lessen NAPQI
formation and thus obviate significant cellular toxicity [7, 8].
4-MP is a competitive antagonist of alcohol dehydrogenase
and a potent CYP450 2E1 inhibitor that is used in the treatment of ethylene glycol and methanol toxicity. 4-MP has been
studied as an alternative to NAC in rats with APAP-induced
hepatotoxicity by Küçükardalı et al. The authors compared
the efficacy of NAC and 4-MP alone and in combination,
ultimately concluding that the two xenobiotics have similar
efficacy in limiting hepatotoxicity, as reflected by lower levels
of serum transaminases and lesser degrees of hepatic necrosis
[9]. In addition, a recent study by Akakpo et al. investigated
the protective effect of 4-MP alone in treatment of APAPinduced liver injury in both mice and primary human hepatocytes. When 4-MP 50 mg/kg was administered with APAP
300 mg/kg, the expected severe liver injury after six hours was
almost completely eliminated. In addition, the use of 4-MP
resulted in inhibiting the formation of APAP-glutathione
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Serum APAP concentration over time
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conjugates, reducing the depletion of liver glutathione stores,
and preventing APAP-induced human hepatocyte cell death.
The 50 mg/kg 4-MP dose used in the mice by Akakpo
et al. is approximately equivalent to 4 mg/kg in humans;
theoretically, 15 mg/kg 4-MP is several times higher than
the effective dose in mice and is also the approved dose for
humans in toxic alcohol poisoning. However, a therapeutic
dose of 4-MP in humans for APAP poisoning would need to
be elucidated [10]. In the presence of 4-MP, NAPQI formation
via CYP450 2E1 is reduced [11]. Two studies demonstrated
that ethanol caused a variable and short-acting induction
of CYP450 2E1 in humans, appearing to involve several
mechanisms including the stabilization of the 2E1 protein
ultimately leading to simultaneous inhibition and induction
[12–14]. Furthermore, acute ethanol ingestion in the setting of
an APAP overdose appears to be hepatoprotective in humans.
The protective effect disappears when ethanol is eliminated
[14, 15]. Given the potential adverse, dose-related effects of
ethanol administration—first-order clearance, intoxication,
and hypoglycemia—4-MP administration would be a preferable substrate. The benefits include simple dosing regimen, no
need to monitor serum concentrations, a wider therapeutic
index, longer duration of action, and more predictable kinetics [16, 17].

APAP is amendable to elimination via HD due to its
molecular weight of 151 Da, Vd of 1 L/kg, and total protein
binding of 10-30%. In addition, use of HD rapidly improves
both severe metabolic derangement and APAP clearance [18].
Ghannoum et al. reported that HD doubles APAP clearance,
and APAP half-life decreased from 5.2 hours to 1.9 hours.
Clearance of NAC is also increased with HD and, thus, the
recommended infusion rate is increased two to three times
while the patient is on HD [2, 17, 19].

4. Conclusion
A novel “triple therapy” with NAC, 4-MP, and HD may be
applicable and have physiologic merit in the case of a patient
suffering from massive APAP poisoning. Further study is
warranted.
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